Immatics Nv Stock Current Valuation
IMTX Stock | USD 10.51 0.59 5.32% |
Valuation analysis of Immatics NV helps investors to measure Immatics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value Multiple is likely to drop to -7.35 in 2024. Fundamental drivers impacting Immatics' valuation include:
Price Book 4.7962 | Enterprise Value 727.6 M | Enterprise Value Ebitda (8.18) | Price Sales 21.9904 | Enterprise Value Revenue 13.4749 |
Undervalued
Today
Please note that Immatics' price fluctuation is not too volatile at this time. Calculation of the real value of Immatics NV is based on 3 months time horizon. Increasing Immatics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Immatics NV is useful when determining the fair value of the Immatics stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Immatics. Since Immatics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Immatics Stock. However, Immatics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. Historical | Market 10.51 | Real 12.8 | Target 19.13 | Hype 10.52 |
The real value of Immatics Stock, also known as its intrinsic value, is the underlying worth of Immatics NV Company, which is reflected in its stock price. It is based on Immatics' financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Immatics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Immatics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Immatics NV helps investors to forecast how Immatics stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Immatics more accurately as focusing exclusively on Immatics' fundamentals will not take into account other important factors: Immatics Current Valuation Analysis
Immatics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
More About Current Valuation | All Equity Analysis
2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 30.4M | 26.3M | 45.9M | 25.2M | Total Assets | 174.6M | 407.8M | 510.0M | 298.3M |
Enterprise Value | = | Market Cap + Debt | - | Cash |
Current Immatics Current Valuation | 727.61 M |
Most of Immatics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Immatics NV is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Immatics Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Immatics is extremely important. It helps to project a fair market value of Immatics Stock properly, considering its historical fundamentals such as Current Valuation. Since Immatics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Immatics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Immatics' interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Competition |
In accordance with the recently published financial statements, Immatics NV has a Current Valuation of 727.61 M. This is 94.93% lower than that of the Biotechnology sector and 84.34% lower than that of the Health Care industry. The current valuation for all United States stocks is 95.62% higher than that of the company.
Immatics Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Immatics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Immatics could also be used in its relative valuation, which is a method of valuing Immatics by comparing valuation metrics of similar companies.Immatics is currently under evaluation in current valuation category among related companies.
Immatics Fundamentals
Return On Equity | -0.44 | ||||
Return On Asset | -0.14 | ||||
Profit Margin | (1.80) % | ||||
Operating Margin | (1.74) % | ||||
Current Valuation | 727.61 M | ||||
Shares Outstanding | 102.98 M | ||||
Shares Owned By Insiders | 24.13 % | ||||
Shares Owned By Institutions | 50.56 % | ||||
Number Of Shares Shorted | 8.39 M | ||||
Price To Earning | 44.61 X | ||||
Price To Book | 4.80 X | ||||
Price To Sales | 21.99 X | ||||
Revenue | 54 M | ||||
Gross Profit | 172.83 M | ||||
EBITDA | (80.65 M) | ||||
Net Income | (96.99 M) | ||||
Cash And Equivalents | 324.38 M | ||||
Cash Per Share | 5.00 X | ||||
Total Debt | 15.4 M | ||||
Debt To Equity | 0.13 % | ||||
Current Ratio | 2.95 X | ||||
Book Value Per Share | 2.66 X | ||||
Cash Flow From Operations | 18.23 M | ||||
Short Ratio | 19.66 X | ||||
Earnings Per Share | (1.30) X | ||||
Price To Earnings To Growth | 3.00 X | ||||
Target Price | 18.67 | ||||
Number Of Employees | 432 | ||||
Beta | 0.69 | ||||
Market Capitalization | 1.19 B | ||||
Total Asset | 509.96 M | ||||
Retained Earnings | (597.29 M) | ||||
Working Capital | 292.82 M | ||||
Z Score | 44.89 | ||||
Net Asset | 509.96 M |
About Immatics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Immatics NV's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immatics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immatics NV based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor based immunotherapies for the treatment of cancer in the United States. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers and Genmab AS to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 388 people.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Immatics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Immatics' short interest history, or implied volatility extrapolated from Immatics options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Immatics Piotroski F Score and Immatics Altman Z Score analysis. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Complementary Tools for Immatics Stock analysis
When running Immatics' price analysis, check to measure Immatics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immatics is operating at the current time. Most of Immatics' value examination focuses on studying past and present price action to predict the probability of Immatics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immatics' price. Additionally, you may evaluate how the addition of Immatics to your portfolios can decrease your overall portfolio volatility.
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
FinTech Suite Use AI to screen and filter profitable investment opportunities |
Is Immatics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immatics. If investors know Immatics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immatics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.30) | Revenue Per Share 0.67 | Quarterly Revenue Growth (0.58) | Return On Assets (0.14) | Return On Equity (0.44) |
The market value of Immatics NV is measured differently than its book value, which is the value of Immatics that is recorded on the company's balance sheet. Investors also form their own opinion of Immatics' value that differs from its market value or its book value, called intrinsic value, which is Immatics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immatics' market value can be influenced by many factors that don't directly affect Immatics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immatics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Immatics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immatics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.